News

January 13, 2017

Biogen Presents New ENDEAR Data Showing SPINRAZA (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation

Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

January 4, 2017

Cure SMA Funding Results in 16 New Research Publications

An important goal of our research funding strategy is to share scientific findings with the broader scientific community. To help accomplish this goal, scientists who recieve Cure SMA funding often publish their findings in peer-reviewed journals. Published articles allow the experiments and results to be reviewed and vetted by other...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

January 4, 2017

2016 Research Year-in-Review: An Historic Year for Our Community

This has been an historic year for the SMA community. On December 23, the FDA announced its approval of Spinraza, the first-ever approved treatment for SMA. 

In addition to the approval of Spinraza, in 2016 the SMA drug pipeline reached notable highs. There are now:

  • 18 active programs
  • 6 programs in...

    READ MORE   |  

Topics: Research, Front Page News

Items 1 - 3 of 134  12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software